To the Editor We read with interest the results of phase 2 of the CAIRO6 trial that showed the feasibility and safety of perioperative chemotherapy in patients with resectable colorectal peritoneal metastases (CPM).1 The major postoperative morbidity was similar in both arms, although the absolute figures showed a lower morbidity in the experimental arm (22% vs 33% in the control arm).
Bhatt A, Passot G, Glehen O. New Insights on the Treatment of Colorectal Peritoneal Metastases From the CAIRO6 Trial. JAMA Surg. 2022;157(2):171. doi:10.1001/jamasurg.2021.5024
Surgery in JAMA: Read the Latest
Customize your JAMA Network experience by selecting one or more topics from the list below.